Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Nurix Therapeutics Q1 GAAP EPS $(0.76) Beats $(0.80) Estimate, Sales $16.59M Miss $16.64M Estimate

Author: Benzinga Newsdesk | April 10, 2024 07:03am
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.80) by 5 percent. This is a 1.33 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $16.59 million which missed the analyst consensus estimate of $16.64 million by 0.33 percent. This is a 30.74 percent increase over sales of $12.69 million the same period last year.

Posted In: NRIX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist